Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
596.76 K
Value Traded
-
Short % Float
-
-12.42%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
379.18 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
29.08 M
Float Shares
-
Insiders
-
Institutions
4.46%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ASPE Catalyst Timeline
Dated clinical, regulatory and corporate events for Aspen Neuroscience, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aspen Neuroscience, Inc.
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How ASPE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ASPE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ARCH Venture Partners XIV, L.P.10% Owner | BuyOffering | 1,200,000 1,200,000 held | $15.00 | 11/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ASPE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ASPE for Q2 2026. | ||||
Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ASPE ranks across every disease it competes in
Competitive Position is a premium feature
See how ASPE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialASPE News
-ASPE
Oct 30, 2026Aspen Neuroscience Announces Pricing of Initial Public Offering
Aspen Neuroscience announced the pricing of its IPO at $15.00 per share, aiming to raise about $140.6 million. The company's shares will start trading on Nasdaq on October 30, 2026, under the ticker symbol 'ASPE'. The offering is set to close on November 2, 2026, pending customary conditions.
Read more →-ASPE
Sep 18, 2026Aspen Neuroscience Announces Publication of Sasineprocel Preclinical Data in "Cell Stem Cell"
Aspen Neuroscience published preclinical data for sasineprocel in Cell Stem Cell. The study showed reproducible manufacturing and no safety issues in a nine-month rodent study. These findings support the company's move into Phase 3 trials for the Parkinson's disease therapy.
Read more →-ASPE
Jul 30, 2026Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ANPD001) to Treat Parkinson's Disease
Aspen Neuroscience announced that its product sasineprocel (ANPD001) received RMAT designation from the FDA for treating Parkinson's Disease. This designation supports expedited development and review, based on positive results from the Phase 1/2a ASPIRO trial. The therapy aims to regenerate lost dopamine neurons and potentially modify disease progression.
Read more →About Aspen Neuroscience, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next ASPE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime